Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (683)	9/11/2002 1:33:12 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3560

VEGF Isoforms, in addition there is VEGF-B, -C, -D,…(C and D are ligands for R-3, abstract for 189 rule) ncbi.nlm.nih.gov Next article suggest that there is no correlation between VEGF-A isoforms and outcome. However, it is known that each isoform (and variant) bind with different strain to R-1, R-2 or R-3,… or that their action may be in connection. Scientists are still at learning curve in regards the true A-mechanisms and VEGF (as well other factors) rule. ncbi.nlm.nih.gov Clin Cancer Res 2002 Jul;8(7):2253-9 Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Division of Gynecology, Molecular Oncology Group, Department of Obstetrics and Gynecology, University of Vienna, A-1090 Vienna, Austria [M. S., D. T., B. F., E. S., A. O., S. L., R. Z.]. PURPOSE: Vascular endothelial growth factor (VEGF) is a promotor for tumor angiogenesis, and is known to be elevated in breast and ovarian cancers. Through alternative splicing six VEGF isoforms were identified. We studied VEGF isoform expression in breast and ovarian cancer cell lines, as well as in breast carcinomas and ovarian tumors, and correlated the expression pattern with the in vitro invasiveness of the breast carcinoma cell lines and the clinicopathologic characteristics of the tumors. Experimental Design: Reverse transcription-PCR and automated laser fluorescence fragment analysis were used to determine the expression of each splice variant. This method allowed the detection of all of the splice variants simultaneously, especially VEGF145 for the first time in tumor tissue. RESULTS: VEGF121 and VEGF165 were the most dominantly expressed variants in all of the tumor samples and cell lines investigated. VEGF145 was very weakly or not expressed in breast and ovarian cancers. Statistical analysis showed no correlation between VEGF splice variant expression in the tumors and histological type, differentiation grade, tumor size, Federation Internationale des Gynaecologistes et Obstetristes, and nodal status from cancer patients. There was also no correlation between the invasive capacity of breast cell lines and VEGF isoform expression. CONCLUSIONS: Even though expression levels of VEGF have been shown to be important for tumor invasion and progression, the present data indicate no relation of VEGF isoform pattern with invasion and progression. Seems that C and D over-expression is related to node-positive BC. ncbi.nlm.nih.gov Back to Avastin, preclinical pharmacology data: jpet.aspetjournals.org Avastin is murine anti-VEGF-A (probably 165 isoform) antibody and does not bind other forms (B,C,D,…) or homolog (PlGF). Trap is combination of the R1 and R2 fragment, so it does bind different VEGF-A isoform, as well as homolg PlGF (probably B but I do not know for C and D). All in all, Avastin failure in mBC may be because of the significant rule of the C and D form, relative to A form, in metastatic BC transformation. Miljenko